UroGen Pharma Ltd.

UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Market Cap

$639M

Revenue

$90M

P/E Ratio

N/A

P/B Ratio

-51.87

D/E Ratio

-14.02

Dividend Yield

0.00%

PEG Ratio

0.22

Net Income

-$127M

Net Profit Margin

-140.35%

Beta

0.398

Gross Margin

0.90%

R/S Growth

5.05

52W Low

$0.00

52W High

$0.00

Updated: July 9 at 19:28:57